-
Je něco špatně v tomto záznamu ?
Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine
Z. Dvořák, H. Sokol, S. Mani
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, přehledy
Grantová podpora
R01 CA222469
NCI NIH HHS - United States
R01 ES030197
NIEHS NIH HHS - United States
- MeSH
- léčivé přípravky * MeSH
- lidé MeSH
- objevování léků MeSH
- pregnanový X receptor * MeSH
- receptory aromatických uhlovodíků * MeSH
- steroidní receptory * MeSH
- střeva MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Research Support, N.I.H., Extramural MeSH
Significant attrition limits drug discovery. The available chemical entities present with drug-like features contribute to this limitation. Using specific examples of promiscuous receptor-ligand interactions, a case is made for expanding the chemical space for drug-like molecules. These ligand-receptor interactions are poor candidates for the drug discovery process. However, provided herein are specific examples of ligand-receptor or transcription-factor interactions, namely, the pregnane X receptor (PXR) and the aryl hydrocarbon receptor (AhR), and itsinteractions with microbial metabolites. Discrete examples of microbial metabolite mimicry are shown to yield more potent and non-toxic therapeutic leads for pathophysiological conditions regulated by PXR and AhR. These examples underscore the opinion that microbial metabolite mimicry of promiscuous ligand-receptor interactions is warranted, and will likely expand the existing chemical space of drugs.
Department of Genetics Albert Einstein College of Medicine Bronx NY 10461 USA
Department of Medicine Albert Einstein College of Medicine Bronx NY 10461 USA
Department of Molecular Pharmacology Albert Einstein College of Medicine Bronx NY 10461 USA
Departments of Cell Biology and Genetics Palacký University Olomouc 78371 Czech Republic
INRA UMR 1319 Micalis and AgroParisTech 78352 Jouy en Josas France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026402
- 003
- CZ-PrNML
- 005
- 20211026132932.0
- 007
- ta
- 008
- 211013s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.tips.2020.09.013 $2 doi
- 035 __
- $a (PubMed)33097284
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Dvořák, Zdeněk $u Departments of Cell Biology and Genetics, Palacký University, Olomouc 78371, Czech Republic. Electronic address: zdenek.dvorak@upol.cz
- 245 10
- $a Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine / $c Z. Dvořák, H. Sokol, S. Mani
- 520 9_
- $a Significant attrition limits drug discovery. The available chemical entities present with drug-like features contribute to this limitation. Using specific examples of promiscuous receptor-ligand interactions, a case is made for expanding the chemical space for drug-like molecules. These ligand-receptor interactions are poor candidates for the drug discovery process. However, provided herein are specific examples of ligand-receptor or transcription-factor interactions, namely, the pregnane X receptor (PXR) and the aryl hydrocarbon receptor (AhR), and itsinteractions with microbial metabolites. Discrete examples of microbial metabolite mimicry are shown to yield more potent and non-toxic therapeutic leads for pathophysiological conditions regulated by PXR and AhR. These examples underscore the opinion that microbial metabolite mimicry of promiscuous ligand-receptor interactions is warranted, and will likely expand the existing chemical space of drugs.
- 650 _2
- $a objevování léků $7 D055808
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a střeva $7 D007422
- 650 12
- $a léčivé přípravky $7 D004364
- 650 12
- $a pregnanový X receptor $7 D000077297
- 650 12
- $a receptory aromatických uhlovodíků $7 D018336
- 650 12
- $a steroidní receptory $7 D011987
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Sokol, Harry $u Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint Antoine, Service de Gastroenterologie, F-75012 Paris, France; INRA, UMR 1319 Micalis and AgroParisTech, 78352 Jouy-en-Josas, France; Paris Centre for Microbiome Medicine FHU, Paris, France
- 700 1_
- $a Mani, Sridhar $u Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: sridhar.mani@einsteinmed.org
- 773 0_
- $w MED00010701 $t Trends in pharmacological sciences $x 1873-3735 $g Roč. 41, č. 12 (2020), s. 900-908
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33097284 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132938 $b ABA008
- 999 __
- $a ok $b bmc $g 1715194 $s 1146909
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 41 $c 12 $d 900-908 $e 20201020 $i 1873-3735 $m Trends in pharmacological sciences $n Trends Pharmacol Sci $x MED00010701
- GRA __
- $a R01 CA222469 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 ES030197 $p NIEHS NIH HHS $2 United States
- LZP __
- $a Pubmed-20211013